Back to GetFilings.com



Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 


 

FORM 10-Q

 

(mark one)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2003

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM                      TO                     

 

COMMISSION FILE NUMBER: 000-33477

 

GENESIS MICROCHIP INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE   77-0584301
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer
Identification No.)

 

2150 GOLD STREET
P.O. BOX 2150
ALVISO, CALIFORNIA
  95002
(Address of principal executive offices)   (Zip Code)

 

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (408) 262-6599

 

Former name, former address and former fiscal year if

changed since last report.

 

Former address: N/A

 

Former Fiscal Year: N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

 

Yes x No ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act):

 

Yes x No ¨

 

There were 32,086,555 shares of the registrant’s common shares issued and outstanding as of December 31, 2003.

 



Table of Contents

GENESIS MICROCHIP INC.

FORM 10-Q

THREE MONTHS ENDED DECEMBER 31, 2003

 

Index

 

Item Number


   Page

Part I: Financial Information

    

Item 1. Financial Statements

    

Condensed Consolidated Balance Sheets at December 31, 2003 and March 31, 2003

   1

Condensed Consolidated Statements of Operations for the three and nine month periods ended December 31, 2003 and December 31, 2002

   2

Condensed Consolidated Statements of Cash Flows for the nine month periods ended December 31, 2003 and December 31, 2002

   3

Notes To Condensed Consolidated Financial Statements

   4

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

   10

Item 3. Quantitative and Qualitative Disclosures About Market Risk

   26

Item 4. Controls and Procedures

   26

Part II: Other Information

    

Item 1. Legal Proceedings

   27

Item 2. Changes in Securities

   *

Item 3. Defaults Upon Senior Securities

   *

Item 4. Submission of Matters to a Vote of Security Holders

   29

Item 5. Other Information

   29

Item 6. Exhibits and Reports on Form 8-K

   29

Signature

   30

 

* No information has been provided because this item is not applicable.

 


Table of Contents

PART I: FINANCIAL INFORMATION

 

ITEM 1: FINANCIAL STATEMENTS

 

GENESIS MICROCHIP INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(amounts in thousands, except per share amounts)

 

     December 31,
2003


   

March 31,

2003


 
     (unaudited)        
ASSETS                 

Current assets:

                

Cash and cash equivalents

   $ 55,850     $ 113,138  

Short-term investments

     68,477       —    

Accounts receivable trade, net of allowance for doubtful accounts of $489 at December 31 and $493 at March 31

     26,208       25,587  

Inventories

     26,779       14,269  

Other

     6,019       5,697  
    


 


Total current assets

     183,333       158,691  

Property and equipment

     16,277       12,770  

Acquired intangibles

     29,232       36,933  

Goodwill

     189,579       189,579  

Deferred income taxes

     2,113       —    

Other

     2,148       4,681  
    


 


Total assets

   $ 422,682     $ 402,654  
    


 


LIABILITIES AND STOCKHOLDERS’ EQUITY                 

Current liabilities:

                

Accounts payable

   $ 24,481     $ 8,640  

Accrued liabilities

     12,485       18,164  

Income taxes payable

     2,475       722  

Loans payable

     335       334  
    


 


Total current liabilities

     39,776       27,860  

Long-term liabilities:

                

Deferred income taxes

     —         961  
    


 


Total liabilities

     39,776       28,821  

Stockholders’ equity:

                

Capital Stock:

                

Preferred stock:

                

Authorized - 5,000 preferred shares, $0.001 par value Issued and outstanding - none at December 31 or March 31

                

Common Stock:

                

Authorized - 100,000 common shares, $0.001 par value Issued and outstanding - 32,087 shares at December 31 and 31,184 shares at March 31

     32       31  

Additional paid-in capital

     390,914       382,587  

Cumulative other comprehensive loss

     (94 )     (94 )

Deferred stock-based compensation

     (3,798 )     (6,809 )

Deficit

     (4,148 )     (1,882 )
    


 


Total stockholders’ equity

     382,906       373,833  
    


 


Total liabilities and stockholders’ equity

   $ 422,682     $ 402,654  
    


 


 

See accompanying notes to condensed consolidated financial statements.

 

1


Table of Contents

GENESIS MICROCHIP INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except per share amounts)

(unaudited)

 

     Three Months Ended
December 31


    Nine Months Ended
December 31


 
     2003

    2002

    2003

    2002

 

Revenues

   $ 56,498     $ 51,682     $ 158,548     $ 139,545  

Cost of revenues (1)

     34,146       32,623       94,013       88,283  
    


 


 


 


Gross profit

     22,352       19,059       64,535       51,262  

Operating expenses:

                                

Research and development (2)

     7,417       8,001       22,522       26,024  

Selling, general and administrative (3)

     9,515       8,942       28,826       26,752  

Amortization of acquired intangibles

     2,654       2,654       7,962       7,973  

Costs associated with patent litigation

     3,529       10,163       9,583       11,561  
    


 


 


 


Total operating expenses

     23,115       29,760       68,893       72,310  
    


 


 


 


Loss from operations

     (763 )     (10,701 )     (4,358 )     (21,048 )

Interest income

     314       590       786       1,422  

Gain on sale of investment

     663       —         663       —    

Imputed interest on lease liability

     —         (160 )     —         (490 )
    


 


 


 


Net interest and other income

     977       430       1,449       932  
    


 


 


 


Income (loss) before income taxes

     214       (10,271 )     (2,909 )     (20,116 )

Provision for (recovery of) income taxes

     35       (3,244 )     (643 )     (4,461 )
    


 


 


 


Net income (loss)

   $ 179     $ (7,027 )   $ (2,266 )   $ (15,655 )
    


 


 


 


Earnings (loss) per share:

                                

Basic

   $ 0.01     $ (0.22 )   $ (0.07 )   $ (0.50 )

Diluted

   $ 0.01     $ (0.22 )   $ (0.07 )   $ (0.50 )

Weighted average number of common shares outstanding:

                                

Basic

     31,948       31,306       31,655       31,445  

Diluted

     33,201       31,306       31,655       31,445  

(1) Amount excludes amortization of acquired developed technology included in amortization of acquired intangibles of:

   $ 1,925     $ 1,925     $ 5,775     $ 5,775  

(2) Amount includes non-cash stock-based compensation of:

   $ 723     $ 1,631     $ 2,162     $ 4,631  

(3) Amount includes non-cash stock-based compensation of:

   $ 207     $ 270     $ 608     $ 1,212  

 

See accompanying notes to condensed consolidated financial statements.

 

2


Table of Contents

GENESIS MICROCHIP INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

(unaudited)

 

     Nine Months Ended

 
     December 31,
2003


    December 31,
2002


 

Cash flows from operating activities:

                

Net loss

   $ (2,266 )   $ (15,655 )

Adjustments to reconcile net loss to cash from operating activities:

                

Depreciation and amortization

     3,569       4,122  

Amortization of acquired intangibles

     7,962       7,973  

Non-cash stock-based compensation

     2,770       5,843  

Deferred income taxes

     (3,074 )     (4,870 )

Gain on sale of investment

     (663 )     —    

Other

     (1 )     519  

Change in operating assets and liabilities:

                

Accounts receivable trade

     (621 )     7,836  

Inventories

     (12,510 )     2,425  

Other current assets

     (322 )     (627 )

Accounts payable

     15,841       2,507  

Accrued liabilities

     (5,679 )     2,340  

Income taxes payable

     1,753       359  
    


 


Net cash from operating activities

     6,759       12,772  

Cash flows used in investing activities:

                

Purchase of short-term investments

     (68,477 )     (3,034 )

Proceeds on sales and maturities of short-term investments

     —         7,836  

Additions to property and equipment

     (6,991 )     (5,657 )

Other

     2,852       (1,413 )
    


 


Net cash used in investing activities

     (72,616 )     (2,268 )

Cash flows provided by financing activities:

                

Proceeds from issue of common stock

     8,569       4,245  

Repurchase of common stock

     —         (3,127 )

Repayment of loans payable

     —         (90 )
    


 


Net cash provided by financing activities

     8,569       1,028  

Increase (decrease) in cash and cash equivalents

     (57,288 )     11,532  

Cash and cash equivalents, beginning of period

     113,138       106,564  
    


 


Cash and cash equivalents, end of period

   $ 55,850     $ 118,096  
 <